Miami When Perth, Australia, November 11, 2022 /PRNewswire/ — Bridgewest Group, a global private investment firm known for developing innovative companies in life sciences, software and deep technology, is expanding its portfolio. Bridgewest Group today announced it has signed a definitive agreement to purchase Pfizer’s sterile injectable manufacturing facility (Perth) Pty Ltd, a subsidiary of Pfizer.
Our cGMP manufacturing facility in Bentley Perth suburb of Western Australiais a diversified sterile injectable manufacturing facility, approved to supply pharmaceuticals in more than 90 countries worldwide, with approvals endorsed by regulatory bodies including FDA, TGA, EU and others. The facility has extensive blow-fill-seal (BFS) capabilities for manufacturing sterile, injectable essential pharmaceutical products, as well as key capabilities for manufacturing specialty oncology drugs for global distribution . In addition to its operations and facilities, Bridgewest Group has acquired a range of pharmaceuticals from Pfizer with the aim of aggressively marketing and expanding globally.
In 2020, Bridgewest Group successfully acquired Hospira Adelaide Pty Ltd, a US-based microbial drug substance manufacturer. Adelaide, which now operates under the name BioCina. BioCina operates as a contract development and manufacturing organization (CDMO) and has enjoyed great success since taking over from Pfizer. Adelaide 30% increase and have a large number of customers from all over the world. Since its acquisition of Bridgewest Group, BioCina has Adelaide Sites contain pDNA and mRNA manufacturing capabilities.
of Perth Operations will be a separate and separate business from BioCina. “We are confident that the experience and expertise gained at BioCina will lead to a smooth transition and subsequent significant growth, further strengthening Bridgewest Group’s commitment to pharmaceutical manufacturing. Australia‘ said Dr. Massoud TaebiCo-founder and CEO of Bridgewest Group.
“We are on great trajectory to complete the sale with Pfizer. We expect the sale to be completed in the next year and we will be working hard on that over the next few months.” Adam Gickling, Executive Vice President and Chief Operating Officer, Bridgewest Group. “After the sale, the facility will continue to supply product to Pfizer under the manufacturing and supply agreement,” Gickling added.
Bridgewest Group has a proven track record across private equity portfolios across multiple industries. In 2005, he expanded his expertise into the life sciences by founding BioDuro-Sundia. BioDuro-Sundia has grown to become his third largest Contract Research, Development and Manufacturing Organization (CRDMO) in the world. Bridgewest Group continues to invest aggressively in several areas including drug discovery/development, cell/gene therapy and medical devices. In addition to BioDuro-Sundia and BioCina, BioAtla, BioOra, Bio4t2, Precision Chroma, Nanophage Technologies, BioViros, and Avasa highlight the current life sciences portfolio.
Doctor Massoud TaebiBridgewest Group Co-Founder and CEO said: Perth is world class and the growth opportunities are huge. Australia has an active and forward-thinking medical community with excellent universities, advanced research, and clinical trial capabilities. Additionally, the Australian government is very active in providing incentives to attract pharmaceutical manufacturing investment to the country. All these factors influenced our decision to invest. Perth clearly aligned with our goal of ensuring pharmaceutical manufacturing in Western Australia long term.Leveraging our experience and resources, we are confident we can continue to build on it. Australian Reputation as a world leader in pharmaceutical manufacturing. ”
About Bridgewest Group
Bridgewest Group is an innovative, privately held global investment firm. $3 billion with private capital. Founded in 1999, this global company has a long standing reputation for creating and scaling innovative businesses to achieve great success. Bridgewest Group leverages its expertise and global eco-community in key sectors where it can have the greatest impact, including biotech, software, semiconductors and artificial intelligence/deep tech. Customized financial investment services and diverse real estate holdings increase equity assets and support the growth of investee companies. Bridgewest Group is based in the United States and invests primarily in the United States. Europe, China and Australia.
Media contact: Jenny Barbieljbourbiel@bridgewestgroup.com
Photo – https://mma.prnewswire.com/media/1944208/Bridgewest_Acquires_Perth_stock_photo.jpg
Logo – https://mma.prnewswire.com/media/1850792/Bridgewest_Group_Logo.jpg
Sourcebridge West Group
Leave a Reply